Abstract 3255: Investigate immune regulation and therapeutic efficacy via regorafenib combined with PD-L1 inhibitor in glioblastoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3255
Abstract: Glioblastoma (GBM) is one of the most common aggressive primary brain tumors, with poor survival despite after surgery, radiation treatment, and chemotherapy. Regorafenib, a tyrosine kinase inhibitor used for cancer treatment, was known to effectively… read more here.
Keywords: glioblastoma; regorafenib; inhibitor; efficacy ... See more keywords
Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo-22-395
Abstract: Background Targeted drug therapy and transcatheter arterial chemoembolization (TACE) is the most effective control method for middle and late-stage hepatocellular carcinoma (HCC). Regorafenib as the second-line treatment of patients with advanced HCC, combined with TACE… read more here.
Keywords: advanced hcc; regorafenib; line; treatment ... See more keywords